Abstract
The electrophysiologic effects of the calcium channel antagonist isradipine in comparison to placebo were evaluated in a double-blind study with 9 patients in each group. The two patient groups were not different with respect to their cardiac disease, baseline electrophysiologic parameters, or blood pressure. Isradipine significantly decreased the systolic ( P < 0.01) and diastolic ( P < 0.05) blood pressure, whereas sinus cycle length was significantly ( P < 0.05) decreased in the placebo group and the isradipine group with no difference between the groups. The influence of isradipine and placebo on sinus node recovery time, effective refractory period of the atrioventricular node, intranodal conduction time (AH interval) and PR interval were not significant. In conclusion, isradipine significantly decreased systolic and diastolic blood pressure. The decrease in sinus cycle length after intravenous isradipine was not significantly different from the decrease seen in the placebo group. Atrioventricular conduction was not significantly affected.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
